CN111166881B - Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof - Google Patents
Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof Download PDFInfo
- Publication number
- CN111166881B CN111166881B CN202010010061.1A CN202010010061A CN111166881B CN 111166881 B CN111166881 B CN 111166881B CN 202010010061 A CN202010010061 A CN 202010010061A CN 111166881 B CN111166881 B CN 111166881B
- Authority
- CN
- China
- Prior art keywords
- epitope
- respiratory syncytial
- syncytial virus
- protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 102
- 229960005486 vaccine Drugs 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 73
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 73
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 18
- 239000002671 adjuvant Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 9
- 108010049048 Cholera Toxin Proteins 0.000 claims description 8
- 102000009016 Cholera Toxin Human genes 0.000 claims description 8
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 8
- 241000320412 Ogataea angusta Species 0.000 claims description 7
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 4
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 206010024612 Lipoma Diseases 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 241001144416 Picornavirales Species 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 108010084592 Saporins Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 241000726445 Viroids Species 0.000 claims description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 28
- 108091007433 antigens Proteins 0.000 abstract description 28
- 102000036639 antigens Human genes 0.000 abstract description 28
- 108010015780 Viral Core Proteins Proteins 0.000 abstract description 26
- 208000006454 hepatitis Diseases 0.000 abstract description 25
- 231100000283 hepatitis Toxicity 0.000 abstract description 25
- 239000012634 fragment Substances 0.000 abstract description 21
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 abstract description 8
- 241000330899 Hepialus Species 0.000 abstract description 6
- 230000028993 immune response Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 238000001338 self-assembly Methods 0.000 abstract description 2
- 241000130660 Hepialidae Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 52
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 46
- 229960000402 palivizumab Drugs 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- 230000003472 neutralizing effect Effects 0.000 description 21
- 230000003053 immunization Effects 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 241000283707 Capra Species 0.000 description 10
- 101710132601 Capsid protein Proteins 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 229940124679 RSV vaccine Drugs 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000001900 immune effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000000003 hoof Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000700721 Hepatitis B virus Species 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000001976 enzyme digestion Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101150050575 URA3 gene Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 210000004201 immune sera Anatomy 0.000 description 5
- 229940042743 immune sera Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 4
- 108010068380 arginylarginine Proteins 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 108010057821 leucylproline Proteins 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 3
- 241000700739 Hepadnaviridae Species 0.000 description 3
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 2
- VRTWYUYCJGNFES-CIUDSAMLSA-N Arg-Ser-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O VRTWYUYCJGNFES-CIUDSAMLSA-N 0.000 description 2
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 2
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 2
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 2
- GGRSYTUJHAZTFN-IHRRRGAJSA-N Asp-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O GGRSYTUJHAZTFN-IHRRRGAJSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 2
- UFNSPPFJOHNXRE-AUTRQRHGSA-N Gln-Gln-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UFNSPPFJOHNXRE-AUTRQRHGSA-N 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- COSBSYQVPSODFX-GUBZILKMSA-N Glu-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N COSBSYQVPSODFX-GUBZILKMSA-N 0.000 description 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 2
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 2
- GECLQMBTZCPAFY-PEFMBERDSA-N Ile-Gln-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GECLQMBTZCPAFY-PEFMBERDSA-N 0.000 description 2
- FUOYNOXRWPJPAN-QEWYBTABSA-N Ile-Glu-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FUOYNOXRWPJPAN-QEWYBTABSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 2
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 2
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 2
- GSSMYQHXZNERFX-WDSOQIARSA-N Leu-Met-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N GSSMYQHXZNERFX-WDSOQIARSA-N 0.000 description 2
- VJGQRELPQWNURN-JYJNAYRXSA-N Leu-Tyr-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJGQRELPQWNURN-JYJNAYRXSA-N 0.000 description 2
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 2
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 2
- QOJDBRUCOXQSSK-AJNGGQMLSA-N Lys-Ile-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O QOJDBRUCOXQSSK-AJNGGQMLSA-N 0.000 description 2
- IIPHCNKHEZYSNE-DCAQKATOSA-N Met-Arg-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O IIPHCNKHEZYSNE-DCAQKATOSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 2
- VADLTGVIOIOKGM-BZSNNMDCSA-N Phe-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CN=CN1 VADLTGVIOIOKGM-BZSNNMDCSA-N 0.000 description 2
- WKLMCMXFMQEKCX-SLFFLAALSA-N Phe-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O WKLMCMXFMQEKCX-SLFFLAALSA-N 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 2
- UVKNEILZSJMKSR-FXQIFTODSA-N Pro-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 UVKNEILZSJMKSR-FXQIFTODSA-N 0.000 description 2
- JFNPBBOGGNMSRX-CIUDSAMLSA-N Pro-Gln-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O JFNPBBOGGNMSRX-CIUDSAMLSA-N 0.000 description 2
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 2
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 2
- CXGLFEOYCJFKPR-RCWTZXSCSA-N Pro-Thr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O CXGLFEOYCJFKPR-RCWTZXSCSA-N 0.000 description 2
- 101150010882 S gene Proteins 0.000 description 2
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 2
- DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 description 2
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 2
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 2
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 2
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 2
- QPPYAWVLAVXISR-DCAQKATOSA-N Ser-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QPPYAWVLAVXISR-DCAQKATOSA-N 0.000 description 2
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 2
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
- XGFYGMKZKFRGAI-RCWTZXSCSA-N Thr-Val-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XGFYGMKZKFRGAI-RCWTZXSCSA-N 0.000 description 2
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- CRWOSTCODDFEKZ-HRCADAONSA-N Tyr-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CRWOSTCODDFEKZ-HRCADAONSA-N 0.000 description 2
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 2
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 108010028295 histidylhistidine Proteins 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960001521 motavizumab Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- CUQUEHYSSFETRD-ACZMJKKPSA-N Asn-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N CUQUEHYSSFETRD-ACZMJKKPSA-N 0.000 description 1
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- RRUWMFBLFLUZSI-LPEHRKFASA-N Asp-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N RRUWMFBLFLUZSI-LPEHRKFASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000633854 Bat hepatitis virus Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- VIRYODQIWJNWNU-NRPADANISA-N Cys-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N VIRYODQIWJNWNU-NRPADANISA-N 0.000 description 1
- BUAUGQJXGNRTQE-AAEUAGOBSA-N Cys-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N BUAUGQJXGNRTQE-AAEUAGOBSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000729176 Fagopyrum dibotrys Species 0.000 description 1
- PSERKXGRRADTKA-MNXVOIDGSA-N Gln-Leu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PSERKXGRRADTKA-MNXVOIDGSA-N 0.000 description 1
- JRHPEMVLTRADLJ-AVGNSLFASA-N Gln-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JRHPEMVLTRADLJ-AVGNSLFASA-N 0.000 description 1
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- UZWUBBRJWFTHTD-LAEOZQHASA-N Glu-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O UZWUBBRJWFTHTD-LAEOZQHASA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- HZMLFETXHFHGBB-UGYAYLCHSA-N Ile-Asn-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZMLFETXHFHGBB-UGYAYLCHSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 101150007280 LEU2 gene Proteins 0.000 description 1
- KTFHTMHHKXUYPW-ZPFDUUQYSA-N Leu-Asp-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KTFHTMHHKXUYPW-ZPFDUUQYSA-N 0.000 description 1
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- XMMWDTUFTZMQFD-GMOBBJLQSA-N Met-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC XMMWDTUFTZMQFD-GMOBBJLQSA-N 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- PCTFVQATEGYHJU-FXQIFTODSA-N Met-Ser-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O PCTFVQATEGYHJU-FXQIFTODSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- KLSOMAFWRISSNI-OSUNSFLBSA-N Pro-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 KLSOMAFWRISSNI-OSUNSFLBSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- OJPHFSOMBZKQKQ-GUBZILKMSA-N Ser-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO OJPHFSOMBZKQKQ-GUBZILKMSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- DZIKVMCFXIIETR-JSGCOSHPSA-N Trp-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O DZIKVMCFXIIETR-JSGCOSHPSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a recombinant respiratory syncytial virus multi-epitope chimeric vaccine, wherein the main target antigen of the vaccine is a recombinant respiratory syncytial virus multi-epitope chimeric protein which consists of a hepialus hepatitis virus core protein and three different antigen epitope fragments of the recombinant respiratory syncytial virus, wherein the three different antigen epitope fragments are respectively inserted into the C end, the N end and an immunodominant region of the hepialus hepatitis virus core protein; wherein, the amino acid sequence of the antigen epitope fragment inserted into the C end and the N end of the hepes hepialid virus core protein is shown as SEQ ID No.2, and the amino acid sequence of the antigen epitope fragment inserted into the immunodominant region of the hepialid hepatitis virus core protein is shown as SEQ ID No. 3. The invention takes the hepialidae hepatitis virus core protein as an epitope presentation carrier to carry out discontinuous presentation of a plurality of epitope fragments, effectively displays different antigen epitopes at the maximum degree and high density on the surface of the virus-like particle, does not influence the self-assembly of the virus-like particle, and has higher immune response effect compared with the epitope presented at a single site.
Description
Technical Field
The invention relates to the field of biomedicine, in particular to a recombinant respiratory syncytial virus multi-epitope chimeric vaccine and a preparation method and application thereof.
Background
Respiratory Syncytial Virus (RSV) is a major pathogen causing lower Respiratory tract infections in infants and young children worldwide, causing bronchiolitis and interstitial pneumonia, causing approximately 20 million deaths per year in children under 5 years of age worldwide [1] Meanwhile, the elderly and the people with immunodeficiency are also the main population infected by RSV. Currently, there are no specific therapeutic drugs and no available prophylactic and therapeutic RSV vaccines other than the humanized monoclonal antibody Palivizumab (Palivizumab) [2]. The RSV genome is 15.2kb in length and encodes 11 proteins including 3 nucleocapsid proteins (N, P, L), 3 transmembrane proteins (F, G, SH), 3 matrix proteins (M, M2-1, M2-2) and 2 nonstructural proteins (NS 1, NS 2). Wherein, the G protein and the F protein respectively mediate the adhesion and fusion of the virus and the cell, and are the main target antigens for the current vaccine development. The F protein has higher homology between the A serotype and the B serotype compared with the G protein, and the RSV vaccine developed by the F protein has protective effect on the A serotype and the B serotype, and is researched by the RSV vaccine at presentThe main target point.
The F protein consists of two subunits of F1 and F2, is a type I glycoprotein and exists in a trimer form. The F protein exists in two states: a metastable pre-fusion state and a more stable post-fusion state; the F protein in a pre-fusion state has higher immunogenicity. It has now been found that there are multiple sites of neutralization on the F protein: i, II, IIIIV, V, VI, VIII andthere are reports on the development of corresponding neutralizing monoclonal antibodies. Wherein, the antigenic site II is the combination site of RSV preventing and treating monoclonal antibody-palivizumab antibody and Motavizumab antibody (Motavizumab), is positioned at amino acids 254 to 277 of F1 subunit of the F protein, is a conformational epitope of an 'alpha helix-ring-alpha helix' secondary structure, and the conformational state of the conformational epitope before and after F protein fusion is kept unchanged [3] Antigenic site VIII is the recently discovered specific site for the pre-fusion F protein, located in the region of amino acids 163-181 of the "helix-loop-helix" and covering in part antigenic site II and/or `>The neutralizing monoclonal antibody hRSV90 recognizing the site has better neutralizing activity to A and B subtypes.
In the last 60 years, the formaldehyde-inactivated RSV (Formalin-inactivated RSV) vaccine can not prevent RSV infection of infants, but also causes serious respiratory disease Enhancement (ERD) to cause death of two infants, and specific target points and mechanisms of the ERD phenomenon are not clear up until now [4] . Therefore, how to circumvent the ERD phenomenon and improve the safety and efficacy of vaccines in RSV vaccine development becomes a primary concern. Although vaccines with F protein as the main component show good immunogenicity in animal experiments, research shows that F protein still has certain safety risk, and ERD phenomenon appears after purified F protein immunizes cotton rats. In recent years, in cases where a vaccine using the fused F protein as a main target antigen has failed clinical trial studies in the elderly population, the vaccine also hasBrings great resistance to the development of RSV vaccine.
Compared with an F protein subunit vaccine, the effective antigen in the epitope chimeric VLP vaccine only selects a palivizumab antibody on RSV F protein to combine with an epitope-epitope II and an epitope VIII, and theoretically, the development strategy is safer for developing the RSV vaccine. The strategy scheme is to select different neutralizing antigen epitopes on RSV F protein and to embed the different neutralizing antigen epitopes into virus-like particles with self-organizing characteristics to form the recombinant multi-epitope embedded virus-like particles.
Human Hepatitis B Virus (HBV) belongs to the genus of orthohepadnaviridae, and a core antigen (HBcAg) of the HBV has the characteristics of self-assembly property, high-density display, strong immunogenicity and the like, and becomes an efficient, safe and widely-applied exogenous epitope presentation carrier [5] . However, pre-existing HBV antibodies in the human population may affect the immune efficacy of HBcAg-based chimeric vaccines in the human population. Because the core antigen of the hepadnaviridae has similar spatial structure and immunogenicity, other hepatitis virus core antigens of the hepadnaviridae can also replace human hepatitis B virus to be used as an epitope display carrier for epitope presentation.
Jeanne H in 2015 for RSV vaccine development [6] The human uses Woodchuck hepatitis Virus core antigen (WHcAg) as an epitope display carrier to perform chimeric display of single epitope of RSV F protein antigen epitope II, obtains a certain immune effect, and proves the feasibility of the epitope display thought of chimeric Virus Like Particles (VLP) for RSV vaccine research and development. However, in order to achieve a certain immune effect, the dose of antigen used for immunizing mice is significantly higher than the conventional dose (100. Mu.g/dose), and the vaccine effectiveness of the chimeric epitope display technology is yet to be enhanced.
In the patent application number of 201710111683.1, an epitope II single epitope is inserted into a Main Immunodominant Region (MIR) region of a core antigen of a hoof hepatitis virus (RBHV), and the constructed cVLP has a certain degree of immunological activity on RSV. However, the technical scheme of the patent is weak in immune response, so that on the basis of the original research, the inventor inserts a plurality of epitope insertion sites of the hepes hoof hepatitis virus, such as an antigen epitope II inserted in an MIR region, and an antigen site VIII inserted at an N terminal and a C terminal, improves the display density and the display type of the antigen epitope on the surface of VLP (VLP) without influencing the particle assembly, and greatly improves the immunological activity of protein. Therefore, a novel preparation scheme of the recombinant respiratory syncytial virus multi-epitope chimeric vaccine is creatively invented, so that the immune effect is effectively improved.
Disclosure of Invention
One aspect of the invention provides a recombinant respiratory syncytial virus multi-epitope chimeric vaccine and a preparation method and application thereof, aiming at the problem of weak immune response of the RSV epitope chimeric VLP vaccine in the prior art.
The technical scheme provided by the invention is as follows:
a recombinant respiratory syncytial virus multi-epitope chimeric vaccine comprises a recombinant respiratory syncytial virus multi-epitope chimeric protein which consists of a hoof-bat hepatitis virus core protein and three different antigen epitope fragments of the recombinant respiratory syncytial virus which are respectively inserted into the C end, the N end and an immunodominant area of the hoof-bat hepatitis virus core protein;
wherein the amino acid sequence of the antigen epitope fragment inserted into the C end and the N end of the Heps hepatica virus core protein is shown as SEQ ID No. 2;
the amino acid sequence of the antigen epitope fragment inserted in the immune dominant region of the hepes hoof hepatitis virus core protein is shown in SEQ ID No. 3.
The present invention relates to a hoof bat hepatitis virus belonging to hepadnaviridae, its host is bat and hoof bat, etc., and is closely related to human hepatitis B virus, woodchuck hepatitis virus and pachinko hepatitis virus on phylogenetic tree, and the RBHV core protein is similar to human hepatitis B virus core antigen structure, and can be self-assembled into virus-like granules (T =4 or T = 3) by 240 or 180 RBHV core proteins. The inventor creatively invents the recombinant multi-epitope chimeric vaccine which is based on RBHV as a carrier and comprises three discontinuous respiratory syncytial virus antigen epitopes on the basis of fully taking the existing results as reference, can stimulate to generate stronger immune response, is used for preventing RSV infection, and has important scientific and application values.
In the present invention, the amino acid sequence of the hepes hepialid virus core protein is different from that of the wild-type hepialid virus core protein, and in order to improve the protein expression amount and protein stability, the present inventors have creatively truncated the N-terminal 28 amino acids of the wild-type virus core antigen (reference sequence: NCBI reference sequence: YP-009045994.1), thereby forming the vector sequence shown in SEQ ID No. 1. Namely, the amino acid sequence of the hepes hoof hepatitis virus core protein is shown in SEQ ID No. 1.
In the present invention, the inventors have found that when a plurality of specific epitope fragments, which are the same or different, are simultaneously inserted into the N-terminus, MIR region and C-terminus of the Hepialus hepaticum virus core protein and are linked between the 78 th and 79 th amino acids by an appropriate amino acid linking arm, different combinations thereof can affect the epitope-displaying effect to different degrees. Wherein the partial combination can enable the epitope fragment to be maximally displayed on the surface of the virus-like particle, and improve the immunological activity of the cVLP.
The virus-like particle is a protein particle formed by self-assembling virus structural proteins, lacks virus nucleic acid, has no infectivity, and can enable antigen epitopes to be repeatedly displayed on the surface of VLP in high density after foreign epitopes are inserted into proper positions of the structural proteins. Therefore, the vaccine prepared by the chimeric VLP technology has the characteristics of safety and high efficiency.
Preferably, in one embodiment of the present invention, the recombinant respiratory syncytial virus multi-epitope chimeric protein assembles into a virus-like particle.
More preferably, in another embodiment of the present invention, said recombinant respiratory syncytial virus multi-epitope chimeric protein forms a virus-like particle in an expression system.
More preferably, in one embodiment of the present invention, the recombinant respiratory syncytial virus multi-epitope chimeric protein is expressed in Hansenula polymorpha to form virus-like particles.
More preferably, in another embodiment of the present invention, said viral vector comprises a hepialis hepatitis virus core protein and an amino acid fragment having the epitope sequence of SEQ ID No.2 inserted into the N-terminal and C-terminal of said hepialis hepatitis virus core protein, and an amino acid fragment having the epitope sequence of SEQ ID No.3 inserted into the MIR region of said hepialis hepatitis virus core protein.
Preferably, in one embodiment of the present invention, the epitope fragment having the epitope sequence shown in SEQ ID No.3 is linked to the amino acids of the immunodominant region of the hepialus hepatitis virus core protein via the connecting arm of GILE amino acid at the N-terminus and the connecting arm of L amino acid at the C-terminus, and the other two epitope fragments having the epitope sequence shown in SEQ ID No.2 are directly linked to the amino acids at the N-terminus and C-terminus of the hepialus hepatitis virus core protein.
Preferably, in one embodiment of the present invention, the amino acid sequence of the recombinant respiratory syncytial virus multi-epitope chimeric protein is shown in SEQ ID No. 4.
More preferably, the recombinant respiratory syncytial virus multi-epitope chimeric protein shown in SEQ ID No.4 is assembled into virus-like particles.
In the recombinant respiratory syncytial virus multi-epitope chimeric vaccine, the selection of an adjuvant plays a crucial role in the final immune response effect of the vaccine. In theory, any suitable pharmaceutical vaccine adjuvant can achieve the objectives of the present invention. Preferably, however, in embodiments of the present invention, the adjuvant comprises aluminum adjuvant, calcium phosphate adjuvant, cholera Toxin (CT), cholera toxin B subunit (CTB), pertussis Toxin (PT), pertussis toxin B subunit (PTB), pertussis Filamentous Hemagglutinin (FHA), pertussis adhesin (PRN), saporin QS-21, alpha-tocopherol, squalene, liposomes (lipomes), monophosphoryl lipid A (MPL-A), MF59, viroid proteoliposomes (Virosomes), polyglycolide (PLA) microspheres, polylactic-glycolic acid (PLGA) microspheres, lipid-cholesterol (DC-Chol), dimethyl dioctadecyl quaternary ammonium bromide (DDA), and mixtures thereof at least one of an immunostimulating complex (ISCOM), montanide ISA50, montanide eISA51, montanide ISA206, montanide ISA720, montanide ISA series adjuvant, AS01, AS02, AS03, AS04, AS series adjuvant, muramyl Dipeptide (MDP), bacterial lipopolysaccharide (OM-174), E.coli heat-Labile Toxin (LT), IL-1, IL-2, IL-6, IL-12, IL-15, IL-18, IFN-gamma, GM-CSF, cpG oligonucleotides, trehalose Dimycolate (TDM), and a substance containing a picornaviral adjuvant of Poly-hypoxanthine nucleotide (Poly I) and/or Poly-cytosine nucleotide (Poly C).
More preferably, in one embodiment of the invention, the adjuvant is MF59 adjuvant.
The invention also provides a preparation method of the recombinant respiratory syncytial virus multi-epitope chimeric vaccine, which is characterized in that the recombinant respiratory syncytial virus multi-epitope chimeric protein is prepared firstly, and the recombinant respiratory syncytial virus multi-epitope chimeric protein is matched with the adjuvant after index detection to obtain the vaccine.
Preferably, the preparation is preferably made in a hansenula polymorpha expression system.
Specifically, the preparation method may further comprise the steps of:
step A) optimization and Synthesis of genes
Optimizing and synthesizing a gene sequence of a hepialis hepatitis virus core protein, which simultaneously contains an amino acid connecting arm and a respiratory syncytial virus multi-epitope chimeric protein fragment gene sequence, according to the preference of hansenula polymorpha codons and the abundance of tRNA;
step B) construction of recombinant plasmid
Replacing the S gene sequence in the vector PUC25-SU with the gene sequence obtained in the step A) to obtain a PUC25-RBRU II recombinant plasmid;
step C) expression and purification of recombinant multiple epitope chimeric proteins
Carrying out enzyme digestion on the recombinant plasmid of the recombinant multi-epitope chimeric protein obtained in the step B) by EcoRI and HindIII, carrying out linearization treatment, carrying out electric transformation into NVSI-H.P-105 (delta URA3 delta LEU 2) Hansenula to obtain a recombinant, screening by an ELISA method to obtain a positive strain with high expression quantity of the recombinant multi-epitope chimeric protein, fermenting, inducing and expressing, harvesting bacteria, carrying out high-pressure crushing, centrifuging, taking a supernatant, and carrying out gel filtration chromatography purification to obtain the recombinant multi-epitope chimeric protein.
Wherein, the gene involved in the step A) is designed, optimized and synthesized according to the amino acid sequence of the chimeric protein.
The vaccines of the present invention may be administered by any suitable means, such as intradermally (i.d.), intraperitoneally (i.p.), intramuscularly (i.m.), intranasally, orally, subcutaneously (s.c.), and the like, and in any suitable delivery device [8] Is used in the preparation of the medicament. Preferably, the vaccine of the invention is administered intradermally, subcutaneously or intramuscularly.
In another aspect of the invention, the invention provides the application of the recombinant respiratory syncytial virus multi-epitope chimeric vaccine in preparing a medicament for preventing and/or treating diseases caused by respiratory syncytial virus infection.
Preferably, the disease caused by respiratory syncytial virus infection is pneumonia, bronchitis or asthma.
In another aspect of the invention, the recombinant respiratory syncytial virus multi-epitope chimeric vaccine is provided for preventing and/or treating diseases caused by respiratory syncytial virus infection.
Preferably, the disease caused by respiratory syncytial virus infection is pneumonia, bronchitis or asthma.
In another aspect of the invention, an antibody is provided, wherein the antibody is obtained by immunizing an individual with the recombinant respiratory syncytial virus multi-epitope chimeric vaccine.
In another aspect of the invention, a strain comprising a polypeptide encoding the above recombinant respiratory syncytial virus multi-epitope chimeric protein is provided. The strain is preferably a yeast strain.
The invention has the beneficial effects that:
the invention provides a recombinant respiratory syncytial virus multi-epitope chimeric vaccine, wherein the recombinant multi-epitope chimeric protein in the vaccine uses a Heps hepatitis virus core protein as a foreign epitope presentation carrier, and firstly carries out discontinuous presentation of a plurality of respiratory syncytial virus epitope fragments, so that the antigen epitope is effectively displayed on the surface of VLP to the maximum extent, the foreign epitope is repeatedly distributed on the surface of VLP in high density, the autonomous assembly of VLP is not influenced, and the vaccine has higher immune effect compared with the presentation of single epitope. The recombinant respiratory syncytial virus multi-epitope chimeric vaccine has the potential of being used as a RSV prophylactic vaccine.
Reference documents:
[1]Groothuis J R,Gutierrez K M,Lauer B A.Respiratory syncytial virusinfection in children with bronchopulmonary dysplasia.[J].Pediatrics,1988,82(2):199-203.
[2]Null D,Bimle C,Weisman L,et al.Palivizumab,a humanized respiratorysyncytial virus monoclonal antibody,reduces hospitalization from respiratorysyncytial virus infection in high-risk infants.The IMpact-RSV Study Group.[J].Pediatrics,1998,102(3Pt 1):531-537.
[3] kingdom medical molecular virology [ M ] science press, 2001.
[4]Kim H W,Canchola J G,Brandt C D,et al.Respiratory syncytial virusdisease in infants despite prior administration of antigenic inactivated vaccine.[J].American Journal of Epidemiology,1969,89(4):422-34.
[5]Salfeld J,Pfaff E,Noah M,et al.Antigenic determinants and functionaldomains in core antigen and e antigen from hepatitis B virus.[J].Journal of Virology,1989,63(2):798-808.
[6]Schickli J H,Whitacre D C,Tang R S,et al.Palivizumab epitope-displayingvirus-like particles protect rodents from RSV challenge.[J].Journal of ClinicalInvestigation,2015,125(4):1637-47.
[7]Prince G A,Curtis S J,Yim K C,et al.Vaccine-Enhanced RespiratorySyncytial Virus Disease in Cotton Rats Following Immunization with Lot 100or aNewly Prepared Reference Vaccine[J].Journal of General Virology,2001,82(12):2881-8.
[8]O"Hagan D T,Valiante N M.Recent advances in the discovery and deliveryof vaccine adjuvants[J].Nature Reviews Drug Discovery,2003,2(9):727-735.
Drawings
FIG. 1 is a schematic diagram showing the construction of a PUC25-RBRU I recombinant plasmid in an example of the present invention;
FIG. 2 is a SDS-PAGE analysis result of the recombinant RSV multi-epitope chimeric protein obtained in the example of the invention, wherein M is Marker, and 1 and 2 are target bands of the recombinant RSV multi-epitope chimeric protein;
FIG. 3 is a graph showing the results of dynamic light scattering of the recombinant respiratory syncytial virus multi-epitope chimeric protein cVLP obtained in the example of the present invention;
FIG. 4 is a transmission electron micrograph of cVLP after phosphotungstic acid negative staining of the recombinant respiratory syncytial virus multi-epitope chimeric protein obtained in the example of the present invention;
FIG. 5 is a graph showing the results of a binding assay between the recombinant RSV multi-epitope chimeric protein obtained in the example of the present invention and a palivizumab antibody;
FIG. 6 is a graph showing the results of a competition test between the recombinant RSV multi-epitope chimeric protein and a palivizumab antibody obtained in the example of the present invention;
FIG. 7 is a graph showing the results of the titer of the antibodies specific to the mouse immune serum protein of the recombinant respiratory syncytial virus multi-epitope chimeric protein obtained in the example of the present invention;
FIG. 8 is a graph showing the results of the titer of antibodies specific to F protein in the mouse immune serum of the recombinant RSV multi-epitope chimeric protein obtained in the example of the present invention;
FIG. 9 is a graph showing the results of neutralizing antibody titer of mouse immune sera against the recombinant respiratory syncytial virus multi-epitope chimeric protein obtained in the example of the present invention;
FIG. 10 is a graph showing the neutralizing antibody titer of the mouse immune serum of the recombinant respiratory syncytial virus multi-epitope chimeric protein and the formaldehyde-inactivated RSV vaccine obtained in the example of the present invention;
FIG. 11 is a graph showing the results of the antibody titer specific to the subtype of the mouse immune serum of the recombinant respiratory syncytial virus multi-epitope chimeric protein and the formaldehyde-inactivated RSV vaccine.
DESCRIPTION OF THE SEQUENCES
SEQ ID No.1 is the amino acid sequence of the hepialus hepatitis virus core protein;
SEQ ID No.2 is the amino acid sequence of the epitope fragment of the recombinant respiratory syncytial virus inserted into the C end and the N end of the Heps trogopus hepatitis virus core protein;
SEQ ID No.3 is the amino acid sequence of the epitope fragment of the recombinant respiratory syncytial virus inserted into the immunodominant region of the Heps fimbristi hepatitis virus core protein;
SEQ ID No.4 is the amino acid sequence of the recombinant respiratory syncytial virus multi-epitope chimeric protein.
Detailed Description
The invention discloses a recombinant respiratory syncytial virus multi-epitope chimeric vaccine, a preparation method and application thereof, and a person skilled in the art can appropriately improve process parameters by referring to the content. It is expressly intended that all such alterations and modifications which are obvious to those skilled in the art are deemed to be incorporated herein by reference, and that the techniques of the invention may be practiced and applied by those skilled in the art without departing from the spirit, scope and range of equivalents of the invention.
In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings that are commonly understood by those skilled in the art. Also, cell culture, molecular genetics, nucleic acid chemistry, immunology laboratory procedures, as used herein, are conventional procedures that are widely used in the relevant art.
In order to make those skilled in the art better understand the technical solution of the present invention, the following detailed description of the present invention is provided with reference to specific embodiments. The experimental procedures, in which specific conditions are not specified, in the preferred examples are generally carried out according to conventional conditions, for example, those described in the molecular cloning protocols (third edition, J. SammBruk et al, huangpetang et al, science publishers, 2002), or according to conditions and procedures recommended by the manufacturers.
Experimental materials:
EcoRI, hindIII restriction enzyme and PCR reagent are all from TaKaRa company;
the RSV F protein is from Beijing Yiqian Shenzhou biotechnology limited and is an insect cell recombinant expression product and a freeze-drying agent;
super Block blocking solution from Thermo corporation;
palivizumab is from Medimmune;
goat anti-human IgG-HRP is from China fir Jinqiao biotechnology, inc. in Beijing;
the MF59 adjuvant is obtained from national institute of Biotechnology, inc.;
the developing solution A, the solution B and the stopping solution C are from Beijing Wantai biological pharmaceutical industry Co., ltd;
BALB/c female mice were from Experimental animals technologies, inc. of Wei Tony, beijing;
the PUC25-SU yeast expression plasmid is from national institute of Biotechnology, inc.;
NVSI-H.P-105 (delta URA3 delta LEU 2) Hansenula was obtained from national institute of Biotechnology, inc.;
RSV A2 strain (ATCC VR 1540) is from the American Type Culture Collection (ATCC);
hep2 cells (ATCC CCL-23) from the American Type Culture Collection (ATCC);
DMEM medium from GIBCO, usa;
fetal bovine serum was from GIBCO, USA;
the dual-resistant enzyme, penicillin-streptomycin, is from GIBCO, USA;
all related gene sequencing and primer synthesis in the following examples were completed by the company Limited in the genome research center of Beijing Noso;
all the related gene synthesis and gene manipulation in the following examples were performed by Shanghai Czeri bioengineering, inc.
The following culture medium formulas are all in percentage by mass and volume:
MD liquid medium: 1.34% of amino acid-free yeast nitrogen source and 2% of glucose;
MM liquid medium: 1.34% of amino acid-free yeast nitrogen source and 0.8% of anhydrous methanol;
SM-leu liquid Medium: 1.34% of amino acid-free yeast nitrogen source, 2% of glucose and 0.01% of leucine;
MM-leu liquid Medium: 1.34% of amino acid-free yeast nitrogen source, 0.8% of anhydrous methanol and 0.01% of leucine;
YPD liquid medium: 1% yeast extract, 2% peptone, 2% glucose;
the solid culture medium is prepared by adding 1.5% agar into the above liquid culture medium, sterilizing at high temperature and high pressure, and storing at low temperature.
The statistical analysis method was performed using SPSS version 18.0.
Example 1: construction and identification of recombinant multi-epitope chimeric protein yeast expression plasmid
1. Design of recombinant multi-epitope chimeric proteins
Taking an amino Sequence of a hepes hoof hepatitis virus core protein (NCBI Reference Sequence: YP _ 009045994.1) as a Reference Sequence, cutting off 28 amino acids at the N end of the Reference Sequence to form a carrier Sequence shown as SEQ ID NO.1, inserting an epitope (shown as SEQ ID NO. 3) of a respiratory syncytial virus fusion protein (Genebank: ACO 83301.1) into an MIR region of the SEQ ID NO.1 Sequence, wherein the epitope is the amino acid epitope at positions 254-277 of the respiratory syncytial virus fusion protein, namely the binding position of a palivizumab antibody, and connecting arms are connected in series through a 'GILE' amino acid and an 'L' amino acid, and simultaneously inserting epitopes (shown as SEQ ID NO. 2) different from the amino acid epitope at positions 163-181 of the chimeric protein of the hepes hoof hepatitis virus core protein at the N end and the C end of the hepes hoof hepatitis virus core protein respectively to form the amino acid Sequence shown as SEQ ID NO. 4.
2. Gene optimization and synthesis
According to the amino acid sequence of the recombinant respiratory syncytial virus multi-epitope chimeric protein shown in SEQ ID No.4, the gene sequence is optimized according to the preference of hansenula polymorpha codons and the abundance of tRNA, a gene sequence is formed, and the sequence is subjected to whole-gene synthesis.
3. Construction of expression plasmids
A gene sequence is replaced by an S gene in an expression vector PUC25-SU yeast expression plasmid by utilizing a gene recombination technology to form a yeast expression plasmid, the plasmid takes 25S rDNA on a hansenula polymorpha genome as a homologous recombination integration arm, URA3 gene as a marker gene, and a MOX promoter is used for efficiently starting the expression of a target protein, and a plasmid construction diagram is shown in figure 1.
4. Restriction enzyme identification and gene sequence determination of expression plasmid
Carrying out EcoRI and HindIII double enzyme digestion identification on a yeast expression plasmid containing the recombinant respiratory syncytial virus multi-epitope chimeric protein, carrying out enzyme digestion for 1 hour at 37 ℃, wherein an enzyme digestion system is shown in Table 1, carrying out 1% agarose gel electrophoresis detection on a product after enzyme digestion, thus the plasmid can be seen to be digested into two gene fragments, namely a large fragment of about 4kb and a small fragment of 1.5kb, wherein the large fragment is a yeast expression frame containing a target gene of the recombinant multi-epitope chimeric protein, and carrying out gene sequence determination on the plasmid, wherein the result shows that the result is consistent with an expected result and no target gene change.
TABLE 1 enzyme digestion System
Example 2: screening and identification of high-expression positive yeast strains
1. Transformation of
Culturing Hansenula polymorpha (NVSI-H.P-105 (DELTA URA3 DELTA LEU 2) in YPD liquid medium to obtain cell density (OD) 600 ) When the expression level reaches 1.0, yeast competence is prepared, large fragment genes in the recombinant multi-epitope chimeric protein yeast expression plasmid subjected to double enzyme digestion by EcoRI and HindIII are converted into NVSI-H.P-105 yeast in an electric conversion mode, and finally the converted bacterial liquid is coated on an SM-leu solid culture medium and cultured for 3 days at 37 ℃ to obtain a recombinant conversion.
2. ELISA screening
Picking single clones grown on SM-leu solid MediumThe colonies were cultured in 2ml of SM-leu liquid medium for culturing cells, and cultured at 37 ℃ for 24 hours with shaking at 220 rpm. Transferring 200 μ l of the bacterial solution into 4ml of SM-leu liquid culture medium, and continuing culturing until the bacterial density (OD) 600 ) After the culture reaches more than 10, centrifuging at 3000rpm to harvest thalli, discarding culture supernatant, suspending the thalli in 4ml of MM-leu culture medium for thalli culture, adding 1% absolute methanol every 6 hours at the stage, inducing the expression of target protein, and inducing for 24 hours; the cells were harvested by centrifugation, 200. Mu.l of yeast cell disruption buffer (20mM PB, pH 7.2) and 200mg of glass beads were added thereto, disrupted by high-frequency low-temperature shaking, and the resultant mixture was treated with a coating solution (Na) 2 CO 3 -NaHCO 3 Solution, pH9.6) diluting the protein supernatant liquid by 500 times, coating the diluted protein supernatant liquid on an enzyme label plate, coating the diluted protein supernatant liquid on the enzyme label plate by 100 mu l/hole for 8 hours at 4 ℃; adding PBS containing 1% BSA, 100. Mu.l/well, blocking at 37 ℃ for 3 hours; the palivizumab antibody was diluted to 1. Mu.g/ml, 100. Mu.l/well, 37 ℃ for 1 hour; diluting goat anti-human IgG-HRP by 10000 times, 100 mul/hole, 37 ℃,1 hour; adding 50 mul of color developing solution A and 50 mul of color developing solution B, developing for 10 minutes at room temperature, and adding 50 mul of stop solution C; and (3) reading OD values at the wavelengths of 450nm and 630nm, and selecting the strain with the highest OD value as the recombinant multi-epitope chimeric protein high-expression yeast strain. Since the selected yeast strain is supplemented with URA3 gene only and can grow in the medium supplemented with leucine only, LEU2 gene is transformed into the selected yeast strain, so that the strain can grow in MD basal medium.
3. Identification of target gene of strain
Extracting the genome of the recombinant multi-epitope chimeric protein high-expression yeast strain, and carrying out sequence determination on the target gene without changing the target gene.
Example 3: preparation and characterization of cVLP
1. Yeast fermentation and cell disruption
The recombinant multi-epitope chimeric protein high-expression yeast strain obtained by screening in the example 2 is inoculated in 10ml of MD liquid culture medium for shaking culture for 24 hours, then is transferred to 100ml of MD liquid culture medium for expanding culture for 24 hours, fermentation seeds are prepared, and are inoculated in a 5L fermentation tank for yeast fermentation culture, and the induction expression of target protein is carried out by using methanol. After completion of the fermentation, the cells were washed 2 times with physiological saline, and finally suspended in a disruption buffer (20mM PB,50mM NaCl, pH 7.2) and disrupted under high pressure, followed by centrifugation to obtain a protein supernatant.
2. Purification of target protein and detection of SDS-PAGE
Purifying by gel filtration chromatography with AKTA chromatography purifier (GE AKTA explorer) with Sephacryl S500-HR as medium and 900ml column volume. After equilibration of the column with 3 column volumes of equilibration buffer (50mMPB, 0.2M NaCl, pH 7.3), 100ml of crude protein concentrate was pumped into the column at a pump rate of 5ml/min, after loading was complete, equilibration buffer continued to flow through the column. When the buffer solution reaches 2/3 column volume (about 550 ml), a second absorption peak appears, and the protein with the absorption peak is collected, namely the target protein.
The purified target protein was analyzed by 12-cent SDS-PAGE electrophoresis, and as a result, the band of the target protein showed a molecular weight of about 30kD, which was substantially identical to the expected band, as shown in FIG. 2.
3. Dynamic light scattering and transmission electron microscopy of vlp
The purified protein was analyzed by dynamic light scattering (Malvern, NANO-ZS 90) and the results are shown in FIG. 3, which shows that the recombinant respiratory syncytial virus multi-epitope chimeric protein cVLP has good size uniformity and average hydrated particle size of about 50nm. The target protein is dripped on a 300-mesh carbon-plated copper net film, the adsorption is carried out for 5 minutes, phosphotungstic acid is negatively dyed for 1 minute, and the particle morphology of the sample is observed by a transmission electron microscope (HITACHI, JEM-1400), so that the result is shown in figure 4, and the cVLP has the size of 30-40nm, uniform size and good morphology.
Example 4: binding and competition assays for recombinant polyepitope chimeric proteins with palivizumab antibodies
1. Palivizumab antibody binding assay
The binding ability of the recombinant multi-epitope chimeric protein to palivizumab was determined using 0.5. Mu.g/ml of purified recombinant multi-epitope chimeric protein, RBHV carrier protein and F protein as the envelope antigen.
And (3) diluting the purified recombinant multi-epitope chimeric protein, RBHV carrier protein and F protein to 0.5 mu g/ml by using a coating solution, coating the enzyme label plate by 100 mu l/hole, and performing reaction at 4 ℃ for 8h. Blocking was performed using Super Block solution, blocking at 37 ℃ for 3h, using palivizumab as the primary antibody, 2-fold gradient dilution at 0.1. Mu.g/ml initial concentration, incubation at 37 ℃ for 1.5h,1: goat anti-human IgG-HRP antibody diluted in 10000 ratios was used as a secondary antibody, incubated at 37 ℃ for 1 hour, developed, and absorbance (OD) values were read at a wavelength of 450nm and 630 nm. The result is shown in fig. 5, the recombinant multi-epitope chimeric protein shows better palivizumab antibody binding capacity, and is slightly stronger than the F protein under the same dosage, which indicates that the recombinant multi-epitope chimeric protein has better epitope display effect.
2. Competitive assay with RSV F protein palivizumab antibody
The ability of the recombinant multi-epitope chimeric protein to compete with the F protein for binding to the palivizumab antibody was determined using 0.5. Mu.g/ml of the F protein as the coating antigen.
RSV F protein was diluted to 0.5. Mu.g/ml using coating solution, 100. Mu.l/well coated microplate, 4 ℃ for 8h. The microplate was blocked with Super Block solution for 3h at 37 ℃. The recombinant multi-epitope chimeric protein and the corresponding carrier RBHV protein are diluted to 80 mu g/ml by Super Block solution, then 2-fold gradient dilution is carried out, and the diluted solution is mixed with equal volume of dilution solution containing 0.1 mu g/ml palivizumab antibody, 100 mu l/hole is carried out, each dilution degree is carried out for 3 multiple holes, the temperature is 37 ℃, and the time is 1.5h. Mixing the following components in parts by weight: goat anti-human IgG-HRP antibody diluted in 10000 proportion was used as a secondary antibody, developed at 37 ℃ for 1 hour, and OD values were read at wavelengths of 450nm and 630 nm. The palivizumab antibody Inhibition rate (Inhibition index) of the recombinant multi-epitope chimeric protein and the corresponding carrier RBHV protein was calculated, wherein the Inhibition rate = [ (palivizumab OD value-sample OD value)/palivizumab OD value ] × 100%, that is, the Inhibition rate = (1-sample OD value/palivizumab OD value) × 100%. As shown in FIG. 6, the recombinant multi-epitope chimeric protein showed a competitive activity with the palivizumab antibody of the F protein, and showed a certain dose relationship, and as the protein concentration decreased, the competitive inhibition rate of the F protein decreased.
Example 5: preparation and immunization of recombinant multi-epitope chimeric vaccine
1. Vaccine preparation
The concentration of the stock solution protein is determined after the recombinant multi-epitope chimeric protein is filtered and sterilized by 0.22 mu m. Diluting the recombinant multi-epitope chimeric protein to 200 mu g/ml, weighing a certain volume of the recombinant multi-epitope chimeric protein according to the immunization dosage, mixing the recombinant multi-epitope chimeric protein with MF59 adjuvant with the same volume to prepare the vaccine, and slowly and reversely mixing the vaccine for 20min at room temperature in a dark place.
2. Vaccine immunization
24 SPF-grade BALB/C female mice 6-8 weeks old were selected and randomly divided into groups A, B, and C3, each group consisting of 8 mice. The following design schemes were used for immunization: group A is injected with 0.3ml of recombinant multi-epitope chimeric vaccine per vaccine; group B injected 0.5. Mu.g of F protein (150. Mu.l) with an equal volume of MF59 adjuvant mixture as a positive control, 0.3 ml/mouse; group C was injected with saline (150. Mu.l) and an equal volume of MF59 adjuvant mixture as an adjuvant control, 0.3 ml/mouse. The immunization was performed by the intraperitoneal route, and each group was immunized 3 times at 2 weeks intervals. Two weeks after the end of the last immunization, blood was collected by cutting the cone and serum was separated.
Example 6: immunological evaluation of recombinant multi-epitope chimeric vaccines
1. Protein specific antibody detection
The recombinant multi-epitope chimeric protein is used as a coating antigen, and an indirect ELISA method is used for detecting a protein specific antibody in mouse immune serum.
The recombinant multi-epitope chimeric protein and the F protein are diluted to 0.1 mu g/ml by using a coating solution, and 100 mu l/hole is coated in an enzyme label plate for 8h at 4 ℃. Blocking by using a SuperBlock solution, blocking for 3h at 37 ℃, diluting the serum to be detected by using the SuperBlock solution in a 3-fold gradient manner, incubating for 1.5h at 37 ℃,1: goat anti-mouse IgG-HRP antibody diluted in 10000 proportion was used as a secondary antibody, incubated at 37 ℃ for 1h, and developed. OD values were read at wavelengths of 450nm and 630nm, with serum vlp-specific antibody titers at the highest dilution fold of serum above Cut-off values (negative control OD Mean + 2-fold Standard Deviation (SD)), and results were expressed as antibody Geometric Mean Titer (GMT) and 95% confidence interval (confidenceinval, CI), and tested for differences between groups using a two-sided independent sample t-test. The results are shown in FIG. 7, the geometric mean titer of the protein-specific antibody of the serum immunized with the recombinant multi-epitope chimeric vaccine is 5.66Log10, the geometric mean titer of the protein-specific antibody of the serum immunized with the F protein MF59 is 5.34Log10, and the results show that the recombinant multi-epitope chimeric vaccine produces higher levels of protein-specific antibody after immunizing mice.
2. RSV F protein specific antibody detection
The RSV F protein specific antibody in the immune serum of the mouse is detected by an indirect ELISA method by taking 0.1 mu g/ml F protein as a coating antigen.
The F protein was diluted to 0.1. Mu.g/ml using the coating solution, 100. Mu.l/well coated microplate, 4 ℃ for 8h. Blocking is carried out by using Super Block solution, blocking is carried out for 3h at 37 ℃, the serum to be detected is diluted by using Super Block in a 3-fold gradient manner, incubation is carried out for 1.5h at 37 ℃,1: goat anti-mouse IgG-HRP antibody diluted in 10000 proportion was used as a secondary antibody, incubated at 37 ℃ for 1h, and developed. OD values were read at wavelengths of 450nm and 630nm, and the maximum dilution factor of serum higher than Cut-off (negative control OD mean +2 SD) was taken as the serum F protein-specific antibody titer, and the results were expressed as GMT and 95% CI, and the inter-group difference test was performed using the double-sided independent sample t-test. The results are shown in fig. 8, the geometric mean titer of the F protein specific antibody of the sera immunized by the recombinant multi-epitope chimeric vaccine is 2.94log10, and the results show that the recombinant multi-epitope chimeric vaccine can generate a certain level of F protein specific antibody after immunizing Balb/c mice.
3. Neutralizing antibody titer detection of immune sera
The specific neutralizing antibody titer of the RSV A2 strain in immune serum is detected by a trace neutralization test method, the result is shown in figure 9, the neutralizing antibody titer of the immune serum of the recombinant multi-epitope chimeric vaccine is 9.875Log2, which shows that the vaccine can generate high-level RSV specific neutralizing antibody after immunizing Balb/c mice, and the recombinant multi-epitope chimeric vaccine has the potential of being used as RSV preventive vaccine.
Example 7: comparison of recombinant multi-epitope chimeric vaccine and Formaldehyde inactivated vaccine
1. Preparation and immunization of formaldehyde inactivated vaccine and recombinant multi-epitope chimeric vaccine
The RSV A2 strain was cultured using Hep2 cells, and the virus was harvested after 3 days at 37 ℃. Method according to Lot100 [7] Preparing formaldehyde inactivated RSV vaccine (FI-RSV), and after the preparation is completed, remaining at 4 ℃ for later use. As described in example 5The method of (3) for preparing a recombinant multiple epitope chimeric vaccine.
24 SPF-grade BALB/C female mice 6-8 weeks old were selected and randomly divided into groups A, B, and C3, each group consisting of 8 mice. The following design schemes were used for immunization: group A is injected with 0.3ml of recombinant multi-epitope chimeric vaccine per vaccine; FI-RSV is injected into the group B, and the volume is 0.1 ml/mouse; group C was injected with saline (150. Mu.l) and an equal volume of MF59 adjuvant mixture as an adjuvant control, 0.3 ml/mouse. The immunization was performed by the intraperitoneal route, and each group was immunized 3 times at 2 weeks intervals. Two weeks after the end of the last immunization, blood was collected by cutting the cone and serum was separated.
2. Neutralizing antibody titer detection of immune sera
The RSV A2 strain-specific neutralizing antibody titer was measured according to the method described in example 6, and the result is shown in FIG. 10, the neutralizing antibody titer of the immune serum of the recombinant multi-epitope chimeric vaccine was 10.00Log2, and the neutralizing antibody titer of the immune serum of FI-RSV was 6.0Log2, which is significantly different (P < 0.001), indicating that Balb/c mice immunized with the recombinant protein vaccine produced high levels of RSV-specific neutralizing antibodies compared with the inactivated formaldehyde vaccine.
3. IgG1 and IgG2a antibody subtype analysis of immune sera
The F protein is used as a coating antigen, and RSV F protein specific IgG and IgG2a antibodies in immune serum of a mouse are detected by an indirect ELISA method.
The F protein was diluted to 0.1. Mu.g/ml using the coating solution, 100. Mu.l/well coated microplate, 4 ℃ for 8h. Blocking is carried out by using Super Block solution, blocking is carried out for 3h at 37 ℃, the serum to be detected is diluted by using Super Block in a 3-fold gradient manner, incubation is carried out for 1.5h at 37 ℃,1: goat anti-mouse IgG1-HRP and goat anti-mouse IgG2a-HRP antibodies diluted in 10000 proportion are respectively used as secondary antibodies, and the secondary antibodies are incubated for 1h at 37 ℃ and developed. OD values were read at 450nm/630nm dual wavelength, with serum F protein specific IgG1 and IgG2a antibody titers as the maximum dilution factor above the Cut-off value (negative control OD mean +2 SD), and the results are expressed as GMT and 95% confidence interval CI. The result is shown in fig. 11, the IgG1 and IgG2a subtype antibody titer levels in the immune serum of the recombinant multi-epitope chimeric vaccine are more balanced than those of the FI-RSV vaccine, which suggests that the vaccine generates more balanced Th1 and Th2 cell immune responses after immunization, immune pathological risks can be avoided to a certain extent, and the vaccine has better safety.
Comparative example 1: the invention relates to a comparison analysis of immunological activities of cVLP (recombinant respiratory syncytial virus) multi-epitope chimeric vaccine (non-continuous multi-epitope) and a patent (application number 201710111683.1)
1. Palivizumab antibody binding assay
The single epitope chimeric protein RBHV-cVLP was prepared according to the design protocol of example 1 and the method described in examples 2 and 3, and the purified RBHV-cVLP was diluted to 0.5. Mu.g/ml, coated on an ELISA plate at 100. Mu.l/well, 4 ℃ for 8h using the coating solution according to the Parley bead antibody binding assay method in example 4. Blocking was performed using Super Block solution, blocking at 37 ℃ for 3h, using palivizumab as the primary antibody, 2-fold gradient dilution at 0.1. Mu.g/ml initial concentration, incubation at 37 ℃ for 1.5h,1: goat anti-human IgG-HRP antibody diluted in 10000 proportion is used as a secondary antibody, incubated for 1h at 37 ℃ and developed. As shown in fig. 5, the recombinant multi-epitope chimeric protein showed good palivizumab antibody binding ability as the single-epitope chimeric protein RBHV-cplp, suggesting that the insertion of the N-terminal and C-terminal foreign epitopes did not affect the assembly characteristics of the particles.
2. Competition assay with RSV F protein palivizumab antibody
The single epitope chimeric protein RBHV-cVLP finally obtained according to the example prepared according to the method described in example 1, 2 and 3 according to the design scheme of example 1, and the RSV F protein was diluted to 0.5. Mu.g/ml, coated on a microplate at 100. Mu.l/well, and 8h according to the palivizumab antibody competition assay method in example 4. The microplate was blocked with Super Block solution for 3h at 37 ℃. RBHV-cVLP was diluted to 80. Mu.g/ml using Super Block solution, then 2-fold gradient diluted, mixed with equal volume of dilution containing 0.1. Mu.g/ml palivizumab antibody, 100. Mu.l/well, 3 replicates per dilution, 37 ℃,1.5h. Mixing the following components in parts by weight: goat anti-human IgG-HRP antibody diluted in 10000 proportion was used as a secondary antibody, and color development was performed at 37 ℃ for 1 hour. The palivizumab antibody inhibition rate of the RBHV-cVLP was calculated. As shown in FIG. 6, the recombinant multi-epitope chimeric protein showed good competitive activity with the F protein palivizumab antibody, as with the single-epitope chimeric protein RBHV-cVLP.
3. Neutralizing antibody titer detection of immune sera
According to the design scheme of example 1, the single epitope chimeric protein RBHV-cVLP is prepared according to the methods of examples 1, 2 and 3, the single epitope chimeric protein RBHV-cVLP is finally obtained, and group D is injected with 30 mu g (150 mu L) of the mixture of the RBHV-cVLP and an equal volume of MF59 adjuvant according to the vaccine preparation and animal immunization method in example 5, and is immunized by the intraperitoneal route, wherein each group is immunized 3 times at intervals of 2 weeks. Mice status and body weight changes were observed daily after immunization of each group of mice. Two weeks after immunization, the broken cone blood is collected and serum is separated, and the RSV specific neutralizing antibody titer level in the serum is detected by using a virus micro-neutralization test method. As shown in FIG. 9, the RSV-specific neutralizing antibody titer of the recombinant respiratory syncytial virus multi-epitope chimeric protein of the invention is about 9.875Log2, while the RSV-specific neutralizing antibody titer of the RBHV-cVLP is about 8.0Log2, and the neutralizing antibody level generated after the recombinant respiratory syncytial virus multi-epitope chimeric protein of the invention adsorbs MF59 adjuvant is improved by 3 times compared with the RBHV-cVLP.
The results indicate that the recombinant respiratory syncytial virus multi-epitope chimeric vaccine has obvious advantages in immune effect, and the recombinant respiratory syncytial virus multi-epitope chimeric vaccine has the potential of being used as a RSV preventive vaccine.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> national institute of Biotechnology, biotechnology Limited
<120> recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof
<130> None
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 189
<212> PRT
<213> Virus
<400> 1
Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Ser Ser Gln Leu Ile
1 5 10 15
Ser Phe Leu Pro Glu Asp Phe Phe Pro Asn Leu Ala Glu Leu Val Glu
20 25 30
Thr Thr Thr Ala Leu Tyr Glu Glu Glu Leu Val Gly Lys Glu His Cys
35 40 45
Ser Pro His His Thr Ala Leu Arg Ser Leu Leu Asn Cys Trp Gly Glu
50 55 60
Thr Val Arg Leu Ile Thr Trp Val Arg Asn Ser Val Glu Gly Pro Leu
65 70 75 80
Ile Gln Asp Ala Ile Val Gln Gln Val Gln Ala Ser Val Gly Leu Arg
85 90 95
Met Arg Gln Leu Met Trp Phe His Leu Ser Cys Leu Thr Phe Gly Gln
100 105 110
Pro Thr Val Ile Glu Phe Leu Val Ser Phe Gly Thr Trp Ile Arg Thr
115 120 125
Pro Gln Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
130 135 140
Glu His Thr Ile Val Arg Arg Arg Gly Gly Ser Arg Ala Thr Arg Ser
145 150 155 160
Pro Arg Arg Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro
165 170 175
Arg Arg Arg Arg Ser Gln Ser Pro Ala Ser Ser Asn Cys
180 185
<210> 2
<211> 19
<212> PRT
<213> Virus
<400> 2
Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys Ala Val
1 5 10 15
Val Ser Leu
<210> 3
<211> 24
<212> PRT
<213> Virus
<400> 3
Asn Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp
1 5 10 15
Gln Lys Lys Leu Met Ser Asn Asn
20
<210> 4
<211> 256
<212> PRT
<213> Artificial
<400> 4
Met Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys Ala
1 5 10 15
Val Val Ser Leu Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Ser Ser
20 25 30
Gln Leu Ile Ser Phe Leu Pro Glu Asp Phe Phe Pro Asn Leu Ala Glu
35 40 45
Leu Val Glu Thr Thr Thr Ala Leu Tyr Glu Glu Glu Leu Val Gly Lys
50 55 60
Glu His Cys Ser Pro His His Thr Ala Leu Arg Ser Leu Leu Asn Cys
65 70 75 80
Trp Gly Glu Thr Val Arg Leu Ile Thr Trp Val Arg Asn Ser Val Glu
85 90 95
Gly Gly Ile Leu Glu Asn Ser Glu Leu Leu Ser Leu Ile Asn Asp Met
100 105 110
Pro Ile Thr Asn Asp Gln Lys Lys Leu Met Ser Asn Asn Leu Pro Leu
115 120 125
Ile Gln Asp Ala Ile Val Gln Gln Val Gln Ala Ser Val Gly Leu Arg
130 135 140
Met Arg Gln Leu Met Trp Phe His Leu Ser Cys Leu Thr Phe Gly Gln
145 150 155 160
Pro Thr Val Ile Glu Phe Leu Val Ser Phe Gly Thr Trp Ile Arg Thr
165 170 175
Pro Gln Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
180 185 190
Glu His Thr Ile Val Arg Arg Arg Gly Gly Ser Arg Ala Thr Arg Ser
195 200 205
Pro Arg Arg Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro
210 215 220
Arg Arg Arg Arg Ser Gln Ser Pro Ala Ser Ser Asn Cys Glu Val Asn
225 230 235 240
Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu
245 250 255
Claims (10)
1. A recombinant respiratory syncytial virus multi-epitope chimeric vaccine comprises a recombinant respiratory syncytial virus multi-epitope chimeric protein, and is characterized in that the amino acid sequence of the recombinant respiratory syncytial virus multi-epitope chimeric protein is shown as SEQ ID No. 4.
2. The recombinant respiratory syncytial virus multi-epitope chimeric vaccine of claim 1, wherein said recombinant respiratory syncytial virus multi-epitope chimeric protein assembles into virus-like particles.
3. The recombinant respiratory syncytial virus multi-epitope chimeric vaccine of claim 1, wherein said recombinant respiratory syncytial virus multi-epitope chimeric vaccine further comprises an adjuvant.
4. The recombinant respiratory syncytial virus multi-epitope chimeric vaccine of claim 3, the adjuvant is selected from aluminum adjuvant, calcium phosphate adjuvant, cholera Toxin (CT), cholera toxin B subunit (CTB), pertussis Toxin (PT), pertussis toxin B subunit (PTB), pertussis Filamentous Hemagglutinin (FHA), pertussis adhesin (PRN), saporin QS-21, alpha-tocopherol, squalene, liposomes (lipomes), monophosphoryl lipid A (MPL-A), MF59, viroid particle lipoproteins (Virosomes), polyglycolide (PLA) microspheres, polylactic-glycolic acid (PLGA) microspheres, lipid-cholesterol (DC-Chol), dimethyldioctadecyl quaternary ammonium bromide (DDA), and mixtures thereof at least one of immunostimulating complex (ISCOM), montanide ISA50, montanide ISA51, montanide ISA206, montanide ISA720, montanide ISA series adjuvant, AS01, AS02, AS03, AS04, AS series adjuvant, muramyl Dipeptide (MDP), bacterial lipopolysaccharide (OM-174), escherichia coli heat-Labile Toxin (LT), IL-1, IL-2, IL-6, IL-12, IL-15, IL-18, IFN-gamma, GM-CSF, cpG oligonucleotide, trehalose Dimycolate (TDM), and a substance containing a picornaviral adjuvant of Poly-hypoxanthine nucleotide (Poly I) and/or Poly-cytosine nucleotide (Poly C).
5. The recombinant respiratory syncytial virus multi-epitope chimeric vaccine according to claim 4, wherein the adjuvant is MF59 adjuvant.
6. A preparation method of the recombinant respiratory syncytial virus multi-epitope chimeric vaccine according to any one of claims 1 to 5, characterized in that the recombinant respiratory syncytial virus multi-epitope chimeric protein is prepared firstly, and the vaccine is obtained by matching the recombinant respiratory syncytial virus multi-epitope chimeric protein with an adjuvant after index detection.
7. The method as claimed in claim 6, wherein the recombinant RSV multi-epitope chimeric protein is prepared in Hansenula polymorpha expression system.
8. Use of the recombinant respiratory syncytial virus multi-epitope chimeric vaccine according to any one of claims 1-5 in the preparation of a medicament for the prevention and/or treatment of a disease caused by respiratory syncytial virus infection.
9. The use according to claim 8, wherein the disease caused by respiratory syncytial virus infection is pneumonia, bronchitis or asthma.
10. A strain comprising a polypeptide encoding the recombinant respiratory syncytial virus polyepitopic chimeric protein of any one of claims 1-5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010010061.1A CN111166881B (en) | 2020-01-06 | 2020-01-06 | Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010010061.1A CN111166881B (en) | 2020-01-06 | 2020-01-06 | Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111166881A CN111166881A (en) | 2020-05-19 |
CN111166881B true CN111166881B (en) | 2023-03-24 |
Family
ID=70619156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010010061.1A Active CN111166881B (en) | 2020-01-06 | 2020-01-06 | Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111166881B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925822B (en) * | 2022-09-01 | 2024-01-09 | 广州源博医药科技有限公司 | Recombinant protein and application thereof in preparation of respiratory syncytial virus vaccine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293741A (en) * | 2014-10-10 | 2015-01-21 | 武汉大学 | Respiratory syncytial virus virus-like particle vaccine as well as preparation method and application thereof |
CN106905434A (en) * | 2017-02-28 | 2017-06-30 | 国药中生生物技术研究院有限公司 | A kind of recombination fusion protein comprising hoof bat hepatitis B core protein and its preparation method and application |
CN106986942A (en) * | 2017-02-28 | 2017-07-28 | 国药中生生物技术研究院有限公司 | A kind of recombination fusion protein comprising bat hepatitis B core protein and its preparation method and application |
CN108456686A (en) * | 2017-02-17 | 2018-08-28 | 厦门大学 | It is a kind of to be used to show peptide carrier of desired polypeptides and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012003064B8 (en) * | 2009-08-13 | 2021-05-25 | Crucell Holland Bv | antibody or antigen-binding fragment thereof, combination comprising them, method of detecting rsv infection, nucleic acid molecules, and method of producing an antibody or antigen-binding fragment thereof |
TWI683826B (en) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | Recombinant rsv antigens |
-
2020
- 2020-01-06 CN CN202010010061.1A patent/CN111166881B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293741A (en) * | 2014-10-10 | 2015-01-21 | 武汉大学 | Respiratory syncytial virus virus-like particle vaccine as well as preparation method and application thereof |
CN108456686A (en) * | 2017-02-17 | 2018-08-28 | 厦门大学 | It is a kind of to be used to show peptide carrier of desired polypeptides and application thereof |
CN106905434A (en) * | 2017-02-28 | 2017-06-30 | 国药中生生物技术研究院有限公司 | A kind of recombination fusion protein comprising hoof bat hepatitis B core protein and its preparation method and application |
CN106986942A (en) * | 2017-02-28 | 2017-07-28 | 国药中生生物技术研究院有限公司 | A kind of recombination fusion protein comprising bat hepatitis B core protein and its preparation method and application |
Non-Patent Citations (1)
Title |
---|
Structural basis of respiratory syncytial virus neutralization by motavizumab;Jason S McLellan 等;《Nature structural & molecular biology》;20100124;第17卷(第2期);Nature structural & molecular biology * |
Also Published As
Publication number | Publication date |
---|---|
CN111166881A (en) | 2020-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112076315B (en) | Nanometer antigen particle fused by novel coronavirus S protein and ferritin subunit, novel coronavirus vaccine, preparation method and application thereof | |
JP7362819B2 (en) | Stabilized soluble prefusion RSV F protein | |
CN112876570B (en) | African swine fever virus vaccine and preparation method thereof | |
KR101801213B1 (en) | Modified rsv f proteins and methods of their use | |
NO313917B1 (en) | Antigen presenting capsid with fused MS2 envelope protein | |
CN111825768B (en) | Self-assembly ferritin-based nano antigen particle, influenza vaccine and preparation method | |
CN110124023B (en) | Novel genetic engineering subunit vaccine of goose astrovirus virus-like particles | |
CN113150083B (en) | Recombinant avian influenza subunit vaccine and preparation method thereof | |
US10125175B2 (en) | Method for enhancing immunogenicity of epitope peptide of HPV antigen, virus-like particle, and method for preparing HPV vaccine | |
CN106636015B (en) | Preparation method of chimeric newcastle disease virus-like particles | |
CN106905434B (en) | Recombinant fusion protein containing hepialus hepatitis virus core protein and preparation method and application thereof | |
CN113862284B (en) | Gene, virus-like particle, vaccine and preparation and application for encoding recombinant avian influenza virus HA protein | |
CN111166881B (en) | Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof | |
WO2023207717A1 (en) | Development and use of broad-spectrum vaccine for h5n8 avian influenza | |
CN110229219B (en) | Preparation method and application of novel respiratory syncytial virus vaccine antigen | |
CN111073861B (en) | Human respiratory syncytial virus strain, application, antibody or hybridoma cell or antiserum | |
CN109851678A (en) | A kind of inferior stable state bovine respiratory syncytial virus of improvement merges DNA molecular and its application of precursor F protein matter and coding | |
CN111138550B (en) | Recombinant respiratory syncytial virus chimeric vaccine and preparation method and application thereof | |
CN114805599B (en) | VLPs based on ADDOmer chimeric porcine O-type foot-and-mouth disease virus epitope and application | |
CN112442130A (en) | Self-assembly ferritin-based nano antigen particle, rabies vaccine prepared from same and application of self-assembly ferritin-based nano antigen particle | |
CN106986942B (en) | Recombinant fusion protein containing core protein of bat hepatitis virus and preparation method and application thereof | |
CN113827714B (en) | H7N9 subtype avian influenza virus-like particle vaccine preparation, preparation and application | |
CN107344969B (en) | Nano influenza vaccine, construction method and application | |
CN106986943B (en) | Recombinant fusion protein containing arctic squirrel hepatitis virus core protein and preparation method and application thereof | |
CN111253494B (en) | Fusion protein of pig foot-and-mouth disease virus and pig rotavirus, viroid particle, vaccine and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |